CONFERENCE PROCEEDING
Stopping smoking prior to elective hip and knee surgery: the impact of visiting a community pharmacist for tobacco management
Barry Finegan 1  
,  
Fadi Hammal 1
,  
 
 
More details
Hide details
1
Department of Anesthesiology and Pain Medicine, University of Alberta, Edmonton, Canada
2
Department of Physical Therapy, University of Alberta, Edmonton, Canada
CORRESPONDING AUTHOR
Barry Finegan   

Department of Anesthesiology and Pain Medicine, University of Alberta, Edmonton, Canada
Publish date: 2018-10-03
 
Tob. Induc. Dis. 2018;16(Suppl 3):A68
KEYWORDS
Download abstract book (PDF)

ABSTRACT
Aim:
To have patients quit smoking prior to elective total joint arthroplasty surgery.

Objective:
Smokers have twice the rate of deep surgical site infections and three times the rate of readmission to hospital after arthroplasty than non-smokers. We assessed the impact of patients obtaining counselling and medical management for their nicotine addiction by visiting a pharmacist in their community on short and long term quit rates.

Methods:
After ethics approval and written informed consent patients attending a pre-surgical assessment clinic were recruited to participate in a pharmacy delivered smoking cessation program. Patients watched a surgery specific video education about the program and smoking status was validated by exhaled CO determination at 30 days after program participation and by self-reported smoking status at 6 months obtained by telephone follow up.

Results:
103 out of 286 (36%) patients approached agreed to participate in the community pharmacist program. 52% were female with a mean age (SD) of 59 (8.4) years. Mean (SD) Fagerstrom score was 4.0 (2.2) and years smoked 36.9 (11.3). 79% had tried to quit previously. Despite all participants agreeing to see a pharmacist only 58% attended for a visit. The validated 30-day and 6-month continuous abstinence rate was 16% and 18%, respectively for those who saw a pharmacist vs. 2% for non-participants.

Conclusion:
Global Research Award for Tobacco Dependence - (GRAND) - Pfizer.

eISSN:1617-9625